- Home
- EML vs TVGN Comparison
EML vs TVGN Comparison
Compare EML & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EML | TVGN |
|---|---|---|
| Founded | 1858 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 89.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EML | TVGN |
|---|---|---|
| Price | $19.40 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 12.0K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $18.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.49 | $0.36 |
| 52 Week High | $29.55 | $1.92 |
Technical Indicators
Market Signals| Indicator | EML | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 39.02 |
| Support Level | $19.28 | $0.36 |
| Resistance Level | $20.22 | $0.40 |
| Average True Range (ATR) | 0.61 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 17.44 | 17.15 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.